Overview

Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
Evaluate effect on cells and patient response to study medications, assess side effects of these medications, and evaluate chemicals in cells that may tell how the drug works, before, and after receiving the study medications.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Emory University
Collaborator:
National Institutes of Health (NIH)
Treatments:
Celecoxib
Erlotinib Hydrochloride